SAM0021

About Samsara Therapeutics

Samsara Therapeutics is a private, pre-clinical biotech pioneering a novel approach to treating neurodegenerative diseases through pharmacological activation of autophagy. The company has built a phenotypic screening platform using patient-derived iPSCs to discover and optimize small molecule autophagy activators, with a pipeline targeting ALS, Parkinson's, and CMT1A. Backed by a $25M Series A led by Apollo Health Ventures and endorsements from major patient advocacy foundations, Samsara is advancing multiple programs toward IND-enabling studies.

Therapeutic Areas

Other Parkinson's Disease (PD) Drugs